Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REATA PHARMACEUTICALS INCRETA · Entity 12293 | Chief Development Officer | February 25, 2019 | February 27, 2019 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | February 29, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REATA PHARMACEUTICALS INC
Report date February 25, 2019 · Filed February 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 8,620 |
Ending reported balance
After 2019-02-26 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2019-02-25 · Conversion · Acquired 15,183 · Balance 23,803 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Row 2 · 2019-02-25 · Sale · Disposed 15,183 · Balance 8,620 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. Row 3 · 2019-02-26 · Conversion · Acquired 25,184 · Balance 33,804 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Row 4 · 2019-02-26 · Sale · Disposed 16,817 · Balance 16,987 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. Row 5 · 2019-02-26 · Sale · Disposed 8,367 · Balance 8,620 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2026-05-25 | Direct | 92,967 |
Reported balance
After 2019-02-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-25 · Exercise / conversion · Disposed 15,183 · Balance 92,967 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2026-05-25 | Direct | 76,150 |
Reported balance
After 2019-02-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-02-26 · Exercise / conversion · Disposed 16,817 · Balance 76,150 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.62 · Expires 2023-06-15 | Direct | 0 |
Reported balance
After 2019-02-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-02-26 · Exercise / conversion · Disposed 8,367 · Balance 0 F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F4: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 15,183 |
Reported balance
After 2019-02-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-25 · Exercise / conversion · Acquired 15,183 · Balance 15,183 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-02-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-25 · Conversion · Disposed 15,183 · Balance 0 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 16,817 |
Reported balance
After 2019-02-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-02-26 · Exercise / conversion · Acquired 16,817 · Balance 16,817 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 25,184 |
Reported balance
After 2019-02-26 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-02-26 · Exercise / conversion · Acquired 8,367 · Balance 25,184 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-02-26 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-02-26 · Conversion · Disposed 25,184 · Balance 0 F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018.
F2: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
F3: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016.
F4: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013.
Skye Bioscience, Inc.
Report date February 29, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2034-03-01 | Direct | 35,000 |
Reported balance
After 2024-02-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-29 · Grant · Acquired 35,000 · Balance 35,000 F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 29, 2024 Filed Mar 4, 2024 11:23 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000025 · wk-form4_1709551390.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 01:32 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 14,110 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001516551-23-000098 · wk-form4_1699320737.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,001 Underlying: Common Stock · 14,110 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 22:17 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 1,472,692 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001516551-23-000056 · wk-form4_1693347437.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,472,692 Underlying: Common Stock · 1,472,692 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 15:42 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001516551-23-000010 · wf-form4_167327894567784.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning December 8, 2022. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 23:50 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantDirector Option Grant (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001516551-21-000025 · wf-form4_163969862196316.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-12-14 F1 · derivative.exercise_date: The Option grant shall be exercisable for a price of $0.058 per Option Share for ten years from December 14, 2021 (the "Grant Date") and the Options will vest in equal monthly installments over the one year period from the Grant Date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 25,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 13 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 25,184 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 8,367 | $11.62 | $97,224.54 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 12 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,184 Underlying: Class A common stock · 8,367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 16,817 | $11.00 | $184,987.00 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 11 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,817 Underlying: Class A common stock · 16,817 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,367 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 10 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B common stock · 8,367 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F4 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,817 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 9 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,150 Underlying: Class B common stock · 16,817 shares Expires 2026-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3 · derivative.exercise_date: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 8,367 | $91.62 | $766,584.54 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · nonDerivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 16,817 | $91.00 | $1,530,347.00 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · nonDerivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,987 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 25,184 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · nonDerivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 15,183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 8 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 15,183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 15,183 | $11.00 | $167,013.00 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 7 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 Underlying: Class A common stock · 15,183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,183 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · derivative · entry 6 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,967 Underlying: Class B common stock · 15,183 shares Expires 2026-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3 · derivative.exercise_date: The options, representing a right to purchase a total of 108,150 shares, vest in sixteen equal quarterly installments beginning on August 25, 2016. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 15,183 | $91.00 | $1,381,653.00 |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:22 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 15,183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-014057 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 11:50 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 4,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-006341 · doc4.xml · derivative · entry 6 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 4,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 11:50 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 4,150 | $11.62 | $48,223.00 |
DisclosureSEC source: 0001209191-19-006341 · doc4.xml · derivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 Underlying: Class A common stock · 4,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 11:50 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,150 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-19-006341 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,367 Underlying: Class B common stock · 4,150 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F5 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 11:50 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 2,750 | $76.97 | $211,661.45 |
DisclosureSEC source: 0001209191-19-006341 · doc4.xml · nonDerivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $76.73 to $77.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 11:50 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 1,400 | $76.17 | $106,640.66 |
DisclosureSEC source: 0001209191-19-006341 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,370 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $75.68 to $76.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 11:50 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 4,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-006341 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 11:25 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 8,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-003672 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 8,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 11:25 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 8,620 | $11.62 | $100,164.40 |
DisclosureSEC source: 0001209191-19-003672 · doc4.xml · derivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 Underlying: Class A common stock · 8,620 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 11:25 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,620 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-19-003672 · doc4.xml · derivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,517 Underlying: Class B common stock · 8,620 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F1 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 14, 2019 Filed Jan 15, 2019 11:25 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 8,620 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-003672 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 14:45 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 4,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-000798 · doc4.xml · derivative · entry 6 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 4,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 14:45 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 4,150 | $11.62 | $48,223.00 |
DisclosureSEC source: 0001209191-19-000798 · doc4.xml · derivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 Underlying: Class A common stock · 4,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 14:45 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,150 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-19-000798 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,137 Underlying: Class B common stock · 4,150 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F5 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 14:45 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 1,320 | $54.58 | $72,045.60 |
DisclosureSEC source: 0001209191-19-000798 · doc4.xml · nonDerivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $54.27 to $55.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 14:45 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 2,830 | $53.71 | $151,999.30 |
DisclosureSEC source: 0001209191-19-000798 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,320 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $53.26 to $54.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 14:45 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 4,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-000798 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2018. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 14:37 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantEmployee Stock Option (right to buy) · Derivative | 34,500 | $0.00 Strike: $55.73 | $0.00 |
DisclosureSEC source: 0001209191-19-000786 · doc4.xml · derivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Class B common stock · 34,500 shares Expires 2029-01-02 F1 · derivative.exercise_date: The options vest in sixteen equal quarterly installments beginning on April 2, 2019, subject to continued service through each vesting date. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057707 · doc4.xml · derivative · entry 6 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 4,750 | $11.62 | $55,195.00 |
DisclosureSEC source: 0001209191-18-057707 · doc4.xml · derivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Class A common stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-18-057707 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,287 Underlying: Class B common stock · 4,750 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F5 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 1,053 | $68.13 | $71,740.89 |
DisclosureSEC source: 0001209191-18-057707 · doc4.xml · nonDerivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $68.00 to $68.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 3,697 | $66.64 | $246,368.08 |
DisclosureSEC source: 0001209191-18-057707 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $66.62 to $67.32. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 11:16 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-057707 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 17:18 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056805 · doc4.xml · derivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 17:18 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 4,750 | $11.62 | $55,195.00 |
DisclosureSEC source: 0001209191-18-056805 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Class A common stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 17:18 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-18-056805 · doc4.xml · derivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,037 Underlying: Class B common stock · 4,750 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F4 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 17:18 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 4,750 | $59.48 | $282,530.00 |
DisclosureSEC source: 0001209191-18-056805 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $59.34 to $59.71. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 17:18 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass A common stock | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056805 · doc4.xml · nonDerivative · entry 1 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 11:01 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | ConversionClass B common stock · Derivative | 14,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-056013 · doc4.xml · derivative · entry 5 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock · 14,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 11:01 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionClass B common stock · Derivative | 14,250 | $11.62 | $165,585.00 |
DisclosureSEC source: 0001209191-18-056013 · doc4.xml · derivative · entry 4 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Class A common stock · 14,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F2 · derivative.exercise_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. F2 · derivative.expiration_date: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 11:01 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 14,250 | $0.00 Strike: $11.62 | $0.00 |
DisclosureSEC source: 0001209191-18-056013 · doc4.xml · derivative · entry 3 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,787 Underlying: Class B common stock · 14,250 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F4 · derivative.exercise_date: The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013. F2 · derivative.underlying: The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 11:01 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | SaleClass A common stock | 14,250 | $57.08 | $813,390.00 |
DisclosureSEC source: 0001209191-18-056013 · doc4.xml · nonDerivative · entry 2 Ward Keith Wayne · CIK 0001662394 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise, conversion and sale reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on one day at prices ranging from $56.84 to $57.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.